


SUPPLEMENTARY APPENDIX**Supplementary appendix 1: Search strategy**

1. exp China/
2. exp Hong Kong/
3. exp Macau/
4. exp Taiwan/
5. exp "Democratic People's Republic of Korea"/
6. exp Japan/
7. exp Mongolia/
8. exp "Republic of Korea"/
9. exp Afghanistan/
10. exp Bangladesh/
11. exp Bhutan/
12. exp India/
13. exp Iran/
14. maldives.mp. or exp Indian Ocean Islands/
15. exp Nepal/
16. exp Pakistan/
17. exp Sri Lanka/
18. exp Brunei/
19. exp Cambodia/
20. exp Indonesia/
21. exp Laos/
22. exp Malaysia/
23. exp Myanmar/
24. exp Philippines/
25. exp Singapore/
26. exp Thailand/
27. timor.mp.
28. exp Vietnam/
29. chronic renal failure.mp. or exp Kidney Failure, Chronic/
30. Glomerular Filtration Rate/
31. exp Proteinuria/
32. exp Hematuria/
33. exp Creatinine/
34. exp Anemia/
35. exp Erythropoietin/
36. exp Iron/
37. exp Ferritins/
38. exp Transferrin/
39. exp Prevalence/
40. exp Epidemiology/
41. exp Cross-Sectional Studies/
42. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28
43. 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38
44. 39 or 40 or 41
45. 42 and 43 and 44
46. limit 45 to yr="2000 -Current"

Supplementary appendix 2: Dendrogram showing grouping of countries into clusters based on country-level sociodemographic characteristics and CKD risk factor prevalence*



*life expectancy at birth, GNI per capita, prevalence of diabetes, prevalence of BP \geq 140/90 mmHg, prevalence of BMI \geq 30 kg/m²

Supplementary appendix 3: Characteristics of the included studies

Reference	Country	Year	Study design; population-based or high-risk	Overall study size	eGFR equation used	Mean age	Female (%)	Study period (years)	Single or multiple eGFR or proteinuria measurements to assess CKD	Overall CKD prevalence	Advanced CKD prevalence	Proteinuria or albuminuria (%)
Cravedi et al. BMJ Open 2012;2:e001357	Bangladesh	2012	Cross-sectional; high-risk	1,518	MDRD	48.0	56.6	0.67	Single	8.6%	1.5%	45.4%
Fatema et al. Saudi J Kidney Dis Transpl 2013;3:534-41	Bangladesh	2013	Cross-sectional; population-based	634	MDRD	36.9	46.0	NR	Single	12.8%	0.0%	8.2%
Khanam et al. J Diabetol 2016;3:2	Bangladesh	2016	Cross-sectional; high-risk	1,317	MDRD	NR	45.3	1	Single	13.9%	NR	NR
Feng et al. Nephrol Dial Transplant 2019;34:1723-30	Bangladesh	2019	Cross-sectional; high-risk	868	CKD-EPI	56.7	63.8	NR	Single	36.4%	1.3%	29.6%
Das et al. PLoS One 2019;14:e0214568	Bangladesh	2019	Cross-sectional; population-based	41,132	CKD-EPI	NR	NR	10.0	Single	27.6%	10.8%	NR
Chen et al. Kidney Int 2005;68:2837-45	China	2005	Cross-sectional; population-based	15,209	MDRD	NR	NR	2	Single	3.0%	0.1%	NR
Li et al. Clinica Chimica Acta 2006;366:209-215	China	2006	Cross-sectional; population-based	2,310	MDRD	60.7	50.5	NR	Single	4.9%	4.9%	8.3%
Liu et al. Clin Chim Acta 2008;387:128-32	China	2008	Cross-sectional; high-risk	13,298	MDRD	50.6	53.6	NR	Single	15.0%	2.0%	8.9%
Sharma et al. Am J Kidney Dis 2010;56:915-27	China	2010	Cross-sectional; population-based	1,999	MDRD	NR	27.4	NR	Single	13.0%	0.6%	20.9%
Chen et al. Clinica Chimica Acta 2010;411:705-9	China	2010	Cross-sectional; population-based	2,969	NR	44.0	41.8	1.7	Single	9.0%	NR	9.0%

Shan et al. Nephrol 2010 15:354-61	China	2010	Cross-sectional; population- based	3,560	MDRD	51.7	45.3	0.9	Single	12.0%	0.1%	4.9%
Luo et al. Vasc Med 2010;15:107-12	China	2010	Prospective; high-risk	3,610	MDRD	67.0	47.0	3.1	Single	19.0%	2.2%	NR
Wang et al. Nephrol Dial Transpl 2010;25:3924-31	China	2010	Cross-sectional; population- based	4,925	MDRD	51.0	51.6	1.2	Single	2.0%	NR	NR
Xu et al. Nephrol Dial Transpl 2011;26:2590-4	China	2011	Cross-sectional; high-risk	1,014	MDRD	68.6	44.9	0.08	Single	26.0%	4.5%	32.7%
Chen et al. Nephrol Dial Transpl 2011;26:1592-9	China	2011	Cross-sectional; population- based	1,289	MDRD	NR	NR	NR	Single	19.0%	0.6%	16.2%
Wang. J Int Med Res 2012;40:1317-24	China	2012	Cross-sectional; high-risk	513	MDRD	49.4	NR	1	Single	11.9%	NR	33.5%
Liu et al. Scand J Urol Nephrol 2012;46:142-7	China	2012	Prospective; population- based	567	MDRD	67.3	39.2	0.25	Single	19.0%	3.0%	NR
Chan et al. J Am Med Dir Assoc 2012;13:630-3	China	2012	Cross-sectional; high-risk	812	CKD-EPI	86.0	66.6	NR	Single	25.6%	4.4%	NR
Liu et al. PLoS One 2012;7:e47100	China	2012	Cross-sectional; population- based	1,186	MDRD	NR	NR	0.17	Single	3.0%	NR	7.2%
Wang et al. PLoS One 2012;7:e38218	China	2012	Cross-sectional; high-risk	1,365	MDRD	62.4	57.7	1.4	Single	2.1%	NR	NR
Miao et al. Cath Cardiovasc Interv 2012;80:361-67	China	2012	Prospective; high-risk	2,862	MDRD	60.5	27.8	1	Single	16.0%	NR	NR
Zheng et al. J Hypertens 2012;30:901-7	China	2012	Prospective; high-risk	3,711	CKD-EPI	56.3	57.2	4.9	Single	3.0%	NR	NR
Li et al. Kidney and Blood Press Res 2012;36:98-106	China	2012	Cross-sectional; population- based	7,053	MDRD	51.3	67.0	1	Single	11.0%	NR	7.8%

Zhang et al. Lancet 2012;379:815-22	China	2012	Cross-sectional; population-based	46,968	CKD-EPI	49.6	NR	3.3	Single	14.2%	0.2%	7.5%
Chen et al. Hong Ling Med J 2013;19:214-21	China	2013	Cross-sectional; high-risk	6,325	MDRD	64.7	46.5	1.9	Single	15.3%	NR	21.3%
Xiong et al. J Formos Med Assoc 2014;113:521-6	China	2014	Cross-sectional; high-risk	785	MDRD	66.6	55.4	10	Single	59.0%	15.2%	NR
Bao et al. QJM 2014;107:443-9	China	2014	Cross-sectional; high-risk	1,012	MDRD	62.8	42.3	2.2	Single	17.0%	NR	NR
Fu et al. Clin Interv Aging 2014;9:301-8	China	2014	Prospective; high-risk	1,050	MDRD	86.0	10.8	1.1	Single	35.4%	NR	NR
Fu et al. PLoS One 2014;9:e101013	China	2014	Cross-sectional; population-based	2,040	MDRD	51.0	61.1	2.2	Single	21.0%	NR	21.3%
Lin et al. BMC Nephrol 2014;15:36	China	2014	Cross-sectional; population-based	10,384	MDRD	52.9	57.0	2.8	Single	13.0%	0.2%	11.5%
Luo et al. Stroke 2014;45:2887-93	China	2014	Cross-sectional; high-risk	17,280	CKD-EPI	63.5	38.6	NR	Single	11.0%	NR	NR
Liu et al. Renal Failure 2015;37:1323-8	China	2015	Cross-sectional; high-risk	1,062	CKD-EPI	79.6	32.1	4.5	Single	41.0%	6.9%	24.8%
Yang et al. BMC Nephrology 2015;16:16	China	2015	Cross-sectional; high-risk	1,115	MDRD	53.2	68.7	0.42	Single	23.0%	NR	20.3%
Luk et al. PLoS One 2015;10:e0134981	China	2015	Cross-sectional; high-risk	2,833	MDRD	58.6	44.4	1.4	Single	5.8%	NR	36%
Wang et al. Nephrology 2015;20:474-84	China	2015	Cross-sectional; high-risk	8,659	CKD-EPI	61.0	52.4	2	Single	10.0%	0.4%	NR
Kong et al. Int Urol Nephrol 2015;47:1547-53	China	2015	Cross-sectional; high-risk	24,002	CKD-EPI	49.9	28.5	1.7	Single	3.0%	NR	1.8%
Zhao et al. PLoS One 2015;10:e0135462	China	2015	Cross-sectional; high-risk	41,862	MDRD	NR	31.5	1	Single	3.0%	NR	NR

Peng et al. Eur J Intern Med 2016;29:78-87	China	2016	Cross-sectional; high-risk	2,161	MDRD	64.6	20.5	2.6	Single	18.0%	NR	NR
Peng et al. Medicine 2016;95:e2740	China	2016	Cross-sectional; high-risk	3,002	MDRD	64.5	20.5	2.4	Single	17.0%	2.2%	NR
Guo et al. J Diabetes Complications 2016;30:803-10	China	2016	Cross-sectional; high-risk	3,301	MDRD	59.3	44.9	8	Single	27.0%	0.8%	25.2%
He et al. Medicine 2016;95:e3769	China	2016	Cross-sectional; population-based	123,629	MDRD	44.8	36.8	NR	Single	5.0%	NR	4.3%
Dong et al. Medicine 2017;e5868	China	2017	Cross-sectional; high-risk	972	MDRD	68.0	46.8	3	Single	13.0%	NR	NR
Sun et al. Chin Med J 2017;130:57-63	China	2017	Cross-sectional; high-risk	1,401	CKD-EPI	58.4	42.8	5.7	Single	39.0%	NR	NR
Yeung et al. J Hepatol 2017;S0168-8278	China	2017	Prospective; high-risk	1,763	CKD-EPI	60.7	44.5	1.2	Single	20.2%	4.5%	47.6%
Inoue et al. BMC Nephrol 2017;18:160	China	2017	Prospective; population-based	7,798	CKD-EPI	51.0	53.3	NR	Single	8.1%	NR	NR
Wang et al. BMC Nephrol 2017;18:188	China	2017	Cross-sectional; population-based	47,204	CKD-EPI	49.6	57.3	8.7	Single	4.0%	NR	11.6%
Wang et al. Biomedical Research 2018;29:3062-8	China	2018	Prospective; high-risk	2,511	Cockcroft-Gault	66.6	27.7	3.3	Single	22.9%	NR	NR
Ma et al. Int Urol Nephrol 2018;50:2239-44	China	2018	Prospective; high-risk	3,237	CKD-EPI	57.9	68.3	3	Single	6.0%	NR	NR
Lin et al. BMJ Open 2018;8:e019097	China	2018	Cross-sectional; high-risk	9,438	MDRD	55.9	71.4	0.49	Single	8.0%	NR	NR
Wang et al. BMC Nephrology 2018;19:294	China	2018	Cross-sectional; population-based	11,578	CKD-EPI	53.8	53.7	0.66	Single	2.0%	NR	NR
Wang et al. PLoS ONE 2018;13:e0193734	China	2018	Cross-sectional; population-based	25,269	CKD-EPI	47.1	52.0	4	Single	10.7%	NR	7.6%

Su et al. Eur J Intern Med 2018;57:32-8	China	2018	Prospective; high-risk	40,524	CKD-EPI	60.6	54.3	2.4	Single	20.0%	6.4%	NR
Wu et al. Scientific Reports 2018;8:2157	China	2018	Prospective; population-based	95,391	CKD-EPI	52.0	20.1	8	Single	14.0%	NR	4.3%
Ye et al. BMC Nephrology 2019;20:457	China	2019	Cross-sectional; high-risk	616	CKD-EPI	41.8	24.0	6.4	Multiple	25.0%	1.0%	12.9%
Ye et al. Medicine 2019;98:e14262	China	2019	Cross-sectional; population-based	2,969,502	CKD-EPI	20.2	49.5	3	Single	2.8%	NR	0.7%
Liu et al. Ann Transl Med 2020;8:2	China	2020	Prospective; high-risk	8,303	CKD-EPI	65.0	62.5	2	Single	9.7%	NR	NR
Prevalence of chronic renal failure in adults in Delhi, India	India	2005	Cross-sectional; population-based	4,712	NR	42.4	43.8	0.25	Multiple	0.8%	NR	4.4%
Unnikrishann et al. Diabetes Care 2007;30:2019-24	India	2007	Cross-sectional; high-risk	1,716	NR	51.0	56.6	NR	Single	29.0%	NR	29.1%
Singh et al. BMC Nephrol 2009;10:4	India	2009	Cross-sectional; population-based	5,252	MDRD	NR	39.9	NR	Single	4.2%	0.4%	2.2%
Varma et al. Nephrol Dial Transpl 2010;25:3011-7	India	2010	Cross-sectional; population-based	3,398	CKD-EPI	35.6	34.0	1.4	Single	11.0%	NR	9.6%
Varma et al. MJAFI 2011;67:9-14	India	2011	Cross-sectional; population-based	1,572	MDRD	34.7	NR	0.58	Single	9.5%	NR	9.9%
Gallieni et al. Nephrol 2013;18:798-07	India	2013	Cross-sectional; population-based	1,526	MDRD	51.0	57.3	1.2	Single	4.1%	0.7%	7.7%
Singh et al. BMC Nephrol 2013;14:114	India	2013	Cross-sectional; high-risk	5,588	CKD-EPI	45.2	44.9	1.9	Single	17.2%	1.6%	13.7%
Anupama and Uma. Indian J Nephrol 2014;24:214-21	India	2014	Cross-sectional; population-based	2,091	MDRD	39.9	54.4	1	Single	6.3%	0.0%	2.9%

Anand et al. <i>Kidney Int</i> 2015;88:178-85	India	2015	Cross-sectional; population-based	9,795	CKD-EPI	42.6	53.5	1.2	Single	8.0%	NR	6.6%
Mahapatra et al. <i>Saudi J Kidney Dis Transpl</i> 2016;27:362-70	India	2016	Cross-sectional; population-based	1,104	MDRD	43.5	38.6	0.4	Single	27.7%	4.4%	23.5%
Trivedi et al. <i>Clin Kidney J</i> 2016;9:438-43	India	2016	Cross-sectional; population-based	2,350	MDRD	48.2	38.8	0.3	Single	20.9%	2.2%	13.8%
Anupama et al. <i>J Hum Hypertens</i> 2017;31:327-32	India	2017	Cross-sectional; population-based	1,331	MDRD	39.0	50.6	2	Single	2.6%	NR	3.6%
Rajput et al. <i>J Diab Metabol</i>	India	2017	Cross-sectional; high-risk	3,000	MDRD	53.4	53.9	0.7	Single	48.4%	2.6%	32.7%
Pradeep et al. <i>Urol Nephrol Open Access J</i> 2018;6:167-71	India	2018	Cross-sectional; population-based	645	MDRD	40.0	39.2	3.1	Single	46.7%	2.0%	36.3%
Tatapudi et al. <i>KI Reports</i> 2019;4:380-9	India	2019	Cross-sectional; population-based	2,210	MDRD	43.2	55.7	NR	Single	18.2%	5.3%	9.0%
O'Callaghan-Gordo et al. <i>BMJ Open</i> 2019;9:e023353	India	2019	Cross-sectional; population-based	12,500	CKD-EPI	41.5	56.5	4.2	Single	1.6%	NR	NR
Mohanty et al. <i>Int J Environ Res and Public Health</i>	India	2020	Cross-sectional; population-based	2,978	MDRD	NR	62.7	NR	Single	14.3%	NR	NR
Prodjosudjadi et al. <i>Nephrol</i> 2009;14:669-74	Indonesia	2009	Cross-sectional; population-based	1,496	MDRD	43.3	63.4	NR	Single	8.6%	1.5%	2.8%
Hosseinpahan et al. <i>BMC Public Health</i> 2009;9:44	Iran	2009	Cross-sectional; population-based	10,063	MDRD	42.7	58.0	3.1	Multiple	14.9%	NR	NR
Najafi et al. <i>PLoS One</i> 2010;5:e14216	Iran	2010	Cross-sectional; high-risk	3,591	MDRD	43.8	61.0	1.8	Single	4.6%	0.3%	NR
Mahdavi-Mazdeh et al. <i>Renal Failure</i> 2010;32:62-8	Iran	2010	Cross-sectional; population-based	31,452	MDRD	43.7	1.6	0.25	Single	6.5%	NR	NR

Barahimi et al. Iran J Kidney Dis 2011;5:374-9	Iran	2011	Cross-sectional; population-based	1,400	MDRD	NR	68.4	NR	Single	5.0%	NR	16.2%
Najafi et al. Arch Iranian Med 2012;15:70-5	Iran	2012	Cross-sectional; high-risk	1,557	MDRD	56.8	53.2	1.7	Single	23.0%	0.5%	5.7%
Malekmakan et al. ISRN Nephrol 2013;2013:427230	Iran	2013	Cross-sectional; high-risk	1,190	MDRD	67.5	59.6	2.3	Single	31.0%	0.3%	NR
Khajehdehi et al. Iranian J Kidney Dis 2014;8:109-15	Iran	2014	Cross-sectional; population-based	9,404	MDRD	39.8	64.1	2.3	Single	11.5%	0.1%	NR
Naghbi et al. Iranian J Kidney Dis 2015;9:449-53	Iran	2015	Cross-sectional; population-based	1,285	MDRD	46.2	59.1	NR	Single	5.1%	NR	7.1%
Panahi et al. Iranian J Kidney Dis 2016;10:274-81	Iran	2016	Prospective; population-based	6,507	CKD-EPI	47.4	56.6	2.5	Single	19.0%	NR	NR
Sepanlou et al. PloS One 2017;12:e0176540	Iran	2017	Prospective; high-risk	11,409	MDRD	56.2	52.6	2	Single	24.0%	0.4%	NR
Bakhshayeshkaram et al. Galen Med J 2018;7:e935	Iran	2018	Cross-sectional; population-based	819	CKD-EPI	43.0	58.5	0.9	Single	16.6%	1.1%	NR
Mahmoodpoor et al. J Renal Inj Prev 2018;7:124-8	Iran	2018	Cross-sectional; population-based	898	MDRD	49.2	54.8	0.3	Single	7.9%	0.0%	NR
Piri-Ardakani et al. Ann Med Health Sci Res 2018;8:26670	Iran	2018	Cross-sectional; population-based	1,800	MDRD	35.5	4.1	NR	Single	10.3%	0.0%	6%
Nakamura et al. Circ J 2006;70:954-9	Japan	2006	Prospective; population-based	7,316	MDRD	52.4	58.4	10	Single	7.0%	0.2%	NR
Iseki et al. Hypertens Res 2007;30:55-62	Japan	2007	Prospective; population-based	154,019	MDRD	49.9	52.0	1	Single	11.0%	0.3%	4.3%
Koganei et al. Circ J 2008;72:179-85	Japan	2008	Prospective; high-risk	1,706	MDRD	63.3	24.2	2.4	Single	42.0%	4.9%	NR

Iguchi et al. Am J Cardiol 2008;102:1056-9	Japan	2008	Prospective; high-risk	41,417	MDRD	NR	66.3	0.7	Single	67.0%	NR	NR
Nakamura et al. Hypertens Res 2009;32:920-6	Japan	2009	Prospective; high-risk	797	Other	64.8	22.1	2.8	Single	29.0%	5.9%	NR
Takamatsu et al. BMC Nephrol 2009;10:34	Japan	2009	Cross-sectional; population-based	1,554	MDRD	62.1	63.1	NR	Single	8.0%	NR	NR
Hamaguchi et al. Circ J 2009;73:1442-7	Japan	2009	Prospective; high-risk	2,013	MDRD	71.5	41.3	NR	Single	71.0%	20.3%	NR
Higashiyama et al. Hypertens Res 2009;32:450-4	Japan	2009	Prospective; high-risk	4,026	Other	63.1	56.9	NR	Single	18.0%	NR	NR
Kohagura et al. Clin Exp Nephrol 2009;13:614-20	Japan	2009	Prospective; population-based	94,602	Other	54.7	58.0	1	Single	16.0%	0.2%	NR
Imai et al. Clin Exp Nephrol 2009;13:621-30	Japan	2009	Cross-sectional; population-based	574,024	Other	NR	58.1	NR	Single	13.2%	0.1%	NR
Kiyosue et al. Circ J 2010;74:786-91	Japan	2010	Prospective; high-risk	572	MDRD	66.4	28.0	3	Single	28.0%	NR	NR
Bouchi et al. Hypertens Res 2010;33:1298-304	Japan	2010	Prospective; high-risk	1,002	MDRD	60.8	45.1	5.2	Single	25.0%	4.7%	43.2%
Nagata et al. Nephrol Dial Transpl 2010;25:2557-64	Japan	2010	Cross-sectional; high-risk	3,297	MDRD	61.6	57.1	NR	Single	18.0%	NR	NR
Yano et al. Atherosclerosis 2011;219:273-9	Japan	2011	Prospective; high-risk	514	Cockcroft-Gault	72.2	62.8	3.4	Single	44.0%	NR	NR
Takata et al. Aging Clin Exp Res 2011;23:223-30	Japan	2011	Prospective; high-risk	595	Other	NR	48.9	NR	Single	69.0%	NR	NR
Konishi et al. Circ J 2011;75:2372-8	Japan	2011	Prospective; high-risk	1,809	Other	59.3	15.0	11.4	Single	17.7%	NR	NR

Kudo et al. Clin Exp Nephrol 2011;15:235-41	Japan	2011	Prospective; high-risk	3,444	MDRD	62.5	54.9	2.5	Single	6.8%	NR	14.9%
Miyatake et al. Environ Health Prev Med 2011;3:191-5	Japan	2011	Cross-sectional; population-based	11,030	Other	42.6	68.6	9	Single	6.0%	NR	2.4%
Shimizu et al. Stroke 2011;42:2531-7	Japan	2011	Prospective; high-risk	11,780	Other	53.8	61.2	17	Single	11.0%	NR	NR
Kudo et al. Clin Exp Nephrol 2012;16:564-9	Japan	2012	Prospective; high-risk	525	Other	74.1	50.1	1	Single	48.0%	NR	25.5%
Hanai et al. Nephrol Dial Transpl 2012;27:1070-5	Japan	2012	Prospective; high-risk	723	Other	63.0	38.7	4.3	Multiple	34.0%	NR	34.0%
Kuwashiro et al. Cerebrovasc Dis 2012;33:141-9	Japan	2012	Prospective; high-risk	876	Other	69.8	38.7	1	Single	37.5%	NR	NR
Dan et al. Circ J 2012;76:2266-72	Japan	2012	Prospective; high-risk	1,177	MDRD	69.1	26.0	3.2	Single	45.6%	3.6%	NR
Ohno et al. Kidney Blood Press Res 2012;36:139-48	Japan	2012	Cross-sectional; high-risk	39,211	Other	58.6	70.3	NR	Single	20.0%	NR	NR
Wakasugi et al. Clin Exp Nephrol 2012;16:259-68	Japan	2012	Cross-sectional; high-risk	49,261	Other	51.6	57.1	NR	Single	10.0%	NR	NR
Furukawa et al. Eur J Endocrinol 2013;169:239-46	Japan	2013	Prospective; high-risk	513	NR	62.0	43.1	NR	Single	32.0%	NR	23.6%
Yano et al. Am J Nephrol 2013;38:195-203	Japan	2013	Prospective; high-risk	1,276	Other	74.2	60.2	NR	Single	50.0%	NR	NR
Konta et al. Clin Exp Nephrol 2013;17:805-10	Japan	2013	Prospective; high-risk	3,445	NR	62.6	55.1	6.2	Multiple	15.0%	NR	14.9%
Noborisaka et al. Environ Health Prev Med 2013;18:466-76	Japan	2013	Cross-sectional; population-based	6,662	Other	NR	40.5	NR	Multiple	18.0%	0.2%	2.2%

Yamada et al. Arch Gerontol Geriatr 2013;57:328-32	Japan	2013	Prospective; high-risk	8,063	MDRD	NR	59.2	2	Multiple	24.0%	NR	NR
Shimizu et al. Atherosclerosis 2014;2014:233:525-9	Japan	2014	Cross-sectional; population-based	4,133	Other	64.5	63.9	7	Single	30.0%	NR	NR
Ishida et al. J Hypertension 2014;32:1435-43	Japan	2014	Cross-sectional; population-based	13,189	Other	53.1	53.3	6.7	Single	12.0%	NR	7.1%
Tsuruya et al. Atherosclerosis 2014;233:260-7	Japan	2014	Cross-sectional; population-based	216,007	NR	63.8	59.0	2	Single	14.0%	NR	NR
Tanaka et al. Nephrology 2015;20:531-8	Japan	2015	Prospective; high-risk	3,231	Other	59.1	38.7	2	Single	43.0%	2.4%	35.1%
Nagai et al. PLoS One 2019;11:e0156792	Japan	2016	Prospective; high-risk	89,547	MDRD	58.6	66.1	17.1	Single	16.8%	0.1%	NR
Nakahashi et al. Heart Vessels 2017;32:22-9	Japan	2017	Prospective; high-risk	577	Other	64.4	21.3	3	Single	31.0%	NR	NR
Hara et al. Clin Exp Nephrol 2017;21:275-82	Japan	2017	Cross-sectional; high-risk	661	MDRD	46.0	9.5	8.7	Multiple	8.5%	NR	NR
Tokoroyama et al. Nephrol Dial Transpl 2017;32:2035-42	Japan	2017	Cross-sectional; high-risk	1,077	Other	63.8	77.2	4.3	Single	25.0%	0.9%	NR
Esato et al. Chest 2017;152:1266-75	Japan	2017	Prospective; high-risk	3,749	NR	73.6	40.7	4.8	NR	35.3%	NR	NR
Hirata et al. Eur J Prev Cardiol 2017;24:505-23	Japan	2017	Cross-sectional; high-risk	7,229	Other	52.5	58.4	NR	Multiple	6.0%	NR	NR
Nishikawa et al. Clin Exp Nephrol 2017;21:316-23	Japan	2017	Prospective; high-risk	13,911	Other	49.3	0.0	7.6	Single	10.4%	0.2%	NR
Yokomichi et al. J Epidemiol 2017;27:S98-106	Japan	2017	Cross-sectional; high-risk	30,834	NR	63.7	35.7	8	Multiple	31.9%	NR	NR

Dan et al. <i>Cardiorenal Med</i> 2018;8:151-9	Japan	2018	Cross-sectional; high-risk	504	MDRD	72.0	26.0	2	Single	49.0%	12.0%	NR
Matsumoto et al. <i>World J Urol</i> 2018;36:	Japan	2018	Cross-sectional; high-risk	594	Other	67.1	18.9	24	Single	35.0%	5.6%	NR
Yanagisawa et al. <i>Heart Rhythm</i> 2018;15:348-54	Japan	2018	Cross-sectional; high-risk	2,091	Cockcroft-Gault	63.1	26.2	9.2	Single	11.0%	1.1%	NR
Kuwabara et al. <i>Nutrients</i> 2018;10:1011	Japan	2018	Cross-sectional; population-based	90,047	MDRD	46.3	50.9	6	Single	5.7%	NR	NR
Kichikawa et al. <i>Cardiovasc Intervent Radiol</i> 2019;42:358-64	Japan	2019	Prospective; high-risk	905	NR	73.5	29.7	2	Single	43.6%	NR	NR
Fujii et al. <i>Nephrol</i> 2019;24:670-73	Japan	2019	Cross-sectional; population-based	11,283	Other	56.0	54.3	NR	Single	8.3%	NR	NR
Toda et al. <i>Nephron</i> 2019;142:91-7	Japan	2019	Cross-sectional; population-based	16,390	MDRD	54.0	32.2	NR	Single	16.2%	NR	7.3%
Kashihara et al. <i>Kidney Int Rep</i> 2019;4:1248-60	Japan	2019	Cross-sectional; high-risk	25,395	NR	72.4	45.0	9.5	Single	56.4%	27.3%	NR
Nagai et al. <i>PLoS One</i> 2019;14:e0216432	Japan	2019	Cross-sectional; high-risk	70,627	Other	NR	54.3	2	Single	16.5%	NR	NR
Tsuyuki et al. <i>Thromb Res</i> 2020;187:39-47	Japan	2020	Cross-sectional; high-risk	2,829	Other	67.5	62.0	4.7	Single	38.0%	6.0%	NR
Hooi et al. <i>Kidney Int</i> 2013;84:1034-40	Malaysia	2013	Cross-sectional; population-based	876	CKD-EPI	42.9	52.1	0.3	Multiple	9.0%	0.6%	13.2%
Abougambou et al. <i>Diabetes Metab Syndr</i> 2013;7:64-7	Malaysia	2013	Prospective; high-risk	1,066	NR	NR	55.8	1	Single	25.4%	NR	25.7%
Ismail et al. <i>BMC Cardiovasc Disord</i> 2018;18:184	Malaysia	2018	Cross-sectional; high-risk	6,563	MDRD	55.4	12.2	7	Single	23.1%	NR	NR

Saminathan et al. BMC Nephrol 2020;21:344	Malaysia	2020	Cross-sectional; population-based	890	CKD-EPI	48.8	58.9	0.8	Multiple	15.5%	0.33%	16.9%
Sharma et al. Am J Kidney Dis 2010;56:915-27	Mongolia	2010	Cross-sectional; population-based	997	MDRD	40.0	74.0	NR	Single	7.8%	1.6%	6.2%
Sharma et al. Am J Kidney Dis 2010;56:915-27	Nepal	2010	Cross-sectional; population-based	8,397	MDRD	NR	38.2	1	Single	14.0%	0.3%	7.4%
Cravedi et al. BMJ Open 2012;2:e001357	Nepal	2012	Cross-sectional; population-based	20,811	MDRD	39.0	61.5	1	Single	18.9%	0.3%	7.1%
Sharma et al. J Nepal Med Assoc 2013;52:205-12	Nepal	2013	Cross-sectional; population-based	1,000	MDRD	42.9	52.1	2	Single	10.6%	NR	5.1%
Jafar et al. Nephrol Dial Transpl 2009;24:2111-6	Pakistan	2009	Cross-sectional; high-risk	2,891	MDRD	51.5	52.3	NR	Single	12.3%	8.0%	12.3%
Ishtiaque et al. PLoS One 2014;9:e85652	Pakistan	2014	Cross-sectional; population-based	1,624	NR	NR	49.0	3.5	Single	17.0%	NR	16.9%
Jessani et al. BMC Nephrol 2014;15:90	Pakistan	2014	Cross-sectional; high-risk	2,873	CKD-EPI	51.5	52.2	1	Single	12.5%	NR	9.4%
Feng et al. Nephrol Dial Transplant 2019;34:1723-30	Pakistan	2019	Cross-sectional; high-risk	685	CKD-EPI	56.7	60.7	2	Single	16.9%	0.9%	16.1%
NNHeS renal report http://goo.gl/XKADci	Philippines	2003	Cross-sectional; population-based	NR	MDRD	NR	NR	2	Single	NR	2.6%	NR
Nang et al. Am J Epidemiol 2009;169:1456-62	Singapore	2009	Cross-sectional; population-based	8,469	MDRD	49.7	51.8	3	Single	53.0%	NR	10.5%
Sabanayagam et al. Nephrol Dial Transpl 2010;25:2564-70	Singapore	2010	Cross-sectional; population-based	4,499	MDRD	49.7	51.9	NR	Single	15.6%	1.5%	12%
Tay et al. Acta Cardiol 2010;65:211-6	Singapore	2010	Prospective; high-risk	5,529	MDRD	62.9	29.0	14	Single	35.0%	9.0%	NR

Feng et al. J Am Geriatr Soc 2012;60:1208-14	Singapore	2012	Prospective; high-risk	1,315	MDRD	65.6	66.2	4	Single	17.0%	NR	NR
Low et al. Ann Acad Med Singapore 2015;44:164-71	Singapore	2015	Cross-sectional; high-risk	1,861	MDRD	57.5	49.9	2.3	Single	53.0%	5.5%	48%
Lew et al. Nephron 2018;138:202-13	Singapore	2018	Cross-sectional; high-risk	88,765	CKD-EPI	65.9	53.3	4	Multiple	25.9%	2.1%	13.8%
Han et al. BMC Nephrol 2009;10:39	South Korea	2009	Cross-sectional; high-risk	944	MDRD	76.0	54.9	3	Single	46.6%	NR	8.4%
Shin et al. BMC Nephrol 2011;12:29	South Korea	2011	Cross-sectional; high-risk	1,363	MDRD	55.6	50.9	5	Single	26.0%	6.7%	NR
Yang et al. Nephrol Dial Transplant 2011;26:3249-255	South Korea	2011	Cross-sectional; high-risk	3,712	MDRD	62.0	54.8	NR	Single	29.0%	NR	29.4%
KNHANES 2011 α	South Korea	2011	Prospective; population-based	5,428	CKD-EPI	NR	NR	4	Single	17.4%	3.8%	7.1%
Park et al. Cardiovasc Therapeutics 2012;30:5-11	South Korea	2012	Cross-sectional; high-risk	1,431	MDRD	63.4	33.9	NR	Single	27.5%	NR	NR
Kim et al. BMC Public Health 2012;12:960	South Korea	2012	Prospective; high-risk	9,509	Other	52.1	52.0	2	Single	13.0%	0.1%	2.3%
Kweon et al. Diabetes Res Clin Pract 2012;3:492-8	South Korea	2012	Cross-sectional; high-risk	10,534	MDRD	NR	60.7	3	Single	26.0%	NR	25.5%
Choi et al. Nephrol Dial Transplant 2012;27:3868-74	South Korea	2012	Cross-sectional; high-risk	11,050	CKD-EPI	63.5	29.5	2.8	Single	27.0%	5.9%	NR
Oh et al. Nephrol Dial Transpl 2012;27:2284-90	South Korea	2012	Cross-sectional; population-based	112,115	MDRD	49.0	46.3	6	Single	3.0%	NR	NR
Kim et al. Jap J Clin Oncol 2013;43:1243-48	South Korea	2013	Cross-sectional; high-risk	1,928	MDRD	54.9	30.7	11	Multiple	10.0%	NR	NR

Hwang et al. Am J Nephrol 2014;40:345-52	South Korea	2014	Prospective; high-risk	4,738	CKD-EPI	62.6	28.5	6	Single	25.0%	NR	NR
Mok et al. PLoS One 2016;11:e0153429	South Korea	2016	Cross-sectional; population-based	367,932	CKD-EPI	41.7	28.0	8	Single	1.0%	NR	3.7%
Lee et al. J Clin Sleep Med 2017;13:1145-52	South Korea	2017	Cross-sectional; population-based	1,732	CKD-EPI	54.0	14.4	15	Single	7.4%	NR	4.8%
Kim et al. Medicine 2018;97:e13099	South Korea	2018	Cross-sectional; high-risk	724	MDRD	50.0	49.0	16.2	Single	10.0%	NR	7%
Kim et al. Int J Cardiol 2018;262:32-7	South Korea	2018	Cross-sectional; high-risk	3,434	MDRD	68.7	33.3	9.6	Single	7.9%	2.5%	NR
Cha et al. Circ J 2018;82:2970-5	South Korea	2018	Cross-sectional; high-risk	12,876	MDRD	64.9	36.5	3	Multiple	28.8%	NR	NR
Lim et al. J Viral Hepa 2019;27:316-22	South Korea	2019	Cross-sectional; high-risk	640	CKD-EPI	63.4	40.5	NR	Single	0.8%	NR	NR
Athuraliya et al. Kidney Int 2011;80:1212-21	Sri Lanka	2011	Cross-sectional; population-based	6,153	MDRD	NR	53.0	NR	Single	4.0%	NR	NR
Jayasekara et al. J Epidemiol 2015;25:275-80	Sri Lanka	2015	Cross-sectional; population-based	87,486	MDRD	NR	48.8	2	Multiple	17.9%	NR	NR
Weeraratna et al. BioMed Res Int 2018;8178043	Sri Lanka	2018	Cross-sectional; high-risk	2,434	MDRD	52.0	35.8	3	Single	16.2%	NR	83.5%
Feng et al. Nephrol Dial Transplant 2019;34:1723-30	Sri Lanka	2019	Cross-sectional; high-risk	796	CKD-EPI	62.9	68.3	2	Single	58.3%	2.4%	44.3%
Ranasinghe et al. BMC Nephrol 2019;20:338	Sri Lanka	2019	Cross-sectional; population-based	30,566	CKD-EPI	57.3	37.1	7	Single	1.8%	NR	NR
Hsu et al. Am J Kidney Dis 2006;48:727-38	Taiwan	2006	Cross-sectional; population-based	6,001	MDRD	NR	50.9	NR	Single	6.0%	NR	NR
Chou et al. Int Med J 2008;38:402-6	Taiwan	2007	Cross-sectional; high-risk	984	MDRD	66.7	45.4	2	Single	16.0%	NR	NR

Kang et al. J Occup Environ Med 2007;49:776-9	Taiwan	2007	Cross-sectional; population-based	3,552	MDRD	53.6	60.1	3	Single	6.0%	NR	NR
Chen et al. Maturitas 2008;59:55-61	Taiwan	2008	Cross-sectional; high-risk	852	MDRD	64.6	56.7	NR	Single	30.9%	NR	NR
Wu et al. Am J Med Sci 2008;336:303-8	Taiwan	2008	Cross-sectional; high-risk	1,133	Cockcroft-Gault	60.7	33.1	12	Multiple	34.7%	5.2%	NR
Cheng et al. Am J Kidney Dis 2008;52:1051-60	Taiwan	2008	Prospective; high-risk	17,026	MDRD	57.2	23.7	5	Multiple	7.0%	NR	NR
Wen et al. Lancet 2008;371:2173-82	Taiwan	2008	Prospective; population-based	462,293	MDRD	41.8	50.2	13	Multiple	11.9%	0.2%	7.9%
Tseng. Clin Biochem 2009;42:1019-24	Taiwan	2009	Cross-sectional; high-risk	549	Cockcroft-Gault	63.4	55.4	2.7	Single	54.0%	NR	54.3%
Lin et al. Nephrol Dial Transplant 2010;25:3230-235	Taiwan	2010	Cross-sectional; high-risk	7,868	MDRD	72.4	39.1	3	Single	43.0%	2.3%	NR
Hsu et al. Nephrology 2011;16:751-7	Taiwan	2011	Cross-sectional; high-risk	27,482	MDRD	58.0	56.4	7	Single	16.0%	NR	10.2%
Lin et al. PLoS One 2012;7:e47960	Taiwan	2012	Prospective; high-risk	2,350	MDRD	NR	51.4	2.8	Multiple	13.0%	NR	12.9%
Lin et al. Cardiovasc Diabetol 2012;11:131	Taiwan	2012	Prospective; high-risk	6,523	MDRD	58.9	48.0	6	Multiple	13.0%	NR	34.6%
Hsieh et al. Cerebrovascular Disease 2014;37:51-6	Taiwan	2014	Prospective; high-risk	657	MDRD	67.3	37.9	5	Single	36.0%	NR	NR
Lin et al. Biomed Res Int 2014;2014:841497	Taiwan	2014	Cross-sectional; high-risk	2,359	MDRD	56.9	51.4	9	Single	4.0%	NR	12.9%
Lin et al. BMC Nephrol 2014;15:66	Taiwan	2014	Prospective; high-risk	3,093	CKD-EPI	63.1	21.8	NR	Single	40.0%	NR	NR
Li et al. Intern Med J 2014;44:645-52	Taiwan	2014	Cross-sectional; population-based	41,600	MDRD	37.9	44.5	2	Single	1.0%	NR	NR

Hsieh et al. J stroke Cerebrovasc Dis 2015;24:673-9	Taiwan	2015	Prospective; high-risk	929	CKD-EPI	64.7	32.4	NR	Single	39.0%	NR	NR
Lin et al. Heart Vess 2015;30:441-50	Taiwan	2015	Prospective; high-risk	2,819	MDRD	62.9	20.9	NR	Single	34.0%	NR	NR
Tsai et al. Eur J Clin Nutr 2015;69:34-9	Taiwan	2015	Cross-sectional; population-based	3,473	MDRD	36.0	48.1	0.4	Single	2.0%	NR	0.5%
Yeh et al. Atherosclerosis 2015;239:328-34	Taiwan	2015	Prospective; high-risk	8,052	CKD-EPI	68.5	38.6	3	Single	41.0%	8.3%	NR
Chang et al. Acta Cardiol Sin 2015;31:106-12	Taiwan	2015	Cross-sectional; population-based	63,129	MDRD	NR	62.5	4	Single	14.8%	0.6%	7.4%
Chua et al. Nephrol 2016;21:583-91	Taiwan	2016	Prospective; high-risk	3,031	CKD-EPI	64.0	21.3	1.2	Single	38.0%	NR	NR
Chu et al. J Am Coll Cardiol 2016;67:S58	Taiwan	2016	Cross-sectional; high-risk	74,431	NR	NR	NR	13	NR	1.9%	NR	NR
Lin et al. BMC Cardiovasc Discord 2017;17:242	Taiwan	2017	Prospective; high-risk	1,394	NR	64.0	26.3	7.7	Single	45.0%	15.7%	NR
Lai et al. Kidney Int 2017;92:703-9	Taiwan	2017	Prospective; population-based	13,805	CKD-EPI	47.5	52.2	2	Single	3.3%	NR	NR
Li et al. BMJ Open 2018;8:e021655	Taiwan	2018	Cross-sectional; high-risk	665	MDRD	62.2	43.5	11.1	Single	34.4%	NR	NR
Chen et al. Environ Pollut 2018;234:838-45	Taiwan	2018	Cross-sectional; high-risk	8,497	CKD-EPI	74.2	49.0	0.5	Single	27.8%	NR	9%
Lai et al. Family Pract 2018;35:259-65	Taiwan	2018	Cross-sectional; population-based	24,826	MDRD	40.6	23.2	2.9	Single	3.4%	NR	3%
Wang et al. Atherosclerosis 2018;269:288-93	Taiwan	2018	Cross-sectional; high-risk	52,752	CKD-EPI	69.5	38.6	9.8	Single	38.0%	8.4%	NR
Tsai et al. Nephron 2018;140:175-84	Taiwan	2018	Prospective; population-based	106,094	CKD-EPI	47.7	60.3	11	Single	9.0%	0.6%	6.2%

Chang et al. BMC Neurol 2019;19:180	Taiwan	2019	Prospective; high-risk	686	Cockcroft-Gault	NR	36.4	2	Single	49.6%	8.0%	NR
Taiwan individual participant data	Taiwan	2007	Cross-sectional; population-based	3142	CKD-EPI	47.7	51.4	1	Single	16.8%	0.9%	13.1%
Domrongkitchaiporn et al. J Am Soc Nephrol 2005;16:791-9	Thailand	2005	Prospective; population-based	3,499	MDRD	54.9	24.1	12	Single	6.8%	NR	2.4%
Chittinandana et al J Med Assoc Thai 2006;89:S112-20	Thailand	2006	Cross-sectional; population-based	15,312	MDRD	45.7	16.6	2	Single	4.7%	0.2%	NR
Perkovic et al. Kidney Int 2008;73:473-9	Thailand	2008	Cross-sectional; population-based	5,099	MDRD	NR	60.4	NR	Single	14.0%	0.6%	NR
Ingsathit et al. Nephrol Dial Transplant 2010;25:1567-75	Thailand	2010	Cross-sectional; population-based	3,459	MDRD	NR	54.6	0.9	Single	14.4%	1.1%	NR
Zaman et al. Diabetes Res Clin Pract 2018;138:238-45	Thailand	2018	Cross-sectional; high-risk	3,748	CKD-EPI	61.4	64.7	0.5	Single	25.0%	NR	NR
Jitraknatee et al. Sci Rep 2020;10:6205	Thailand	2020	Cross-sectional; high-risk	1,094	CKD-EPI	61.6	57.1	1	Single	24.4%	6.1%	52.9%
Ito et al. Nephron Clin Pract 2008;109:c25-32	Vietnam	2008	Cross-sectional; high-risk	8,505	MDRD	57.2	64.8	NR	Single	4.7%	0.2%	NR
Tran et al. BMC Res Notes 2017;10:523	Vietnam	2017	Cross-sectional; population-based	2,037	MDRD	42.3	54.4	NR	Single	12.8%	0.1%	11.4%

eGFR=estimated glomerular filtration rate; CKD-EPI=chronic kidney disease epidemiology equation; MDRD=Modification of Diet in Renal Disease equation; NR=not reported; N/A=not applicable

Supplementary appendix 4: Quality assessment of the included studies[^]

Study	Representativeness of the sample	Sample size	Comparability of characteristics	Definition of CKD	Quality of descriptive statistics reporting	Total score
Cravedi et al. BMJ Open 2012;2:e001357	1	0	0	1	1	3
Fatema et al. Saudi J Kidney Dis Transpl 2013;3:534-41	1	0	0	1	1	3
Khanam et al. J Diabetol 2016;3:2	0	0	1	1	1	3
Feng et al. Nephrol Dial Transplant 2019;34:1723-30	0	0	0	1	1	2
Das et al. PLoS One 2019;14:e0214568	1	1	1	1	1	5
Chen et al. Kidney Int 2005;68:2837-45	1	1	1	1	1	5
Li et al. Clinica Chimica Acta 2006;366:209-215	1	0	0	1	1	3
Liu et al. Clinc Chim Acta 2008;387:128-32	0	1	1	1	1	4
Sharma et al. Am J Kidney Dis 2010;56:915-27	0	1	0	1	1	3
Chen et al. Clinica Chimica Acta 2010;411:705-9	1	0	1	1	1	4
Shan et al. Nephrol 2010 15:354-61	1	1	0	0	1	3
Luo et al. Vasc Med 2010;15:107-12	0	1	1	1	1	4
Wang et al. Nephrol Dial Transpl 2010;25:3924-31	1	1	1	1	1	5
Xu et al. Nephrol Dial Transpl 2011;26:2590-4	0	0	1	1	1	3
Chen et al. Nephrol Dial Transpl 2011;26:1592-9	1	0	0	1	1	3
Wang. J Int Med Res 2012;40:1317-24	0	0	0	0	0	0
Liu et al. Scand J Urol Nephrol 2012;46:142-7	0	0	1	1	1	3
Chan et al. J Am Med Dir Assoc 2012;13:630-3	0	0	0	1	1	2
Liu et al. PLoS One 2012;7:e47100	1	0	0	1	1	3
Wang et al. PloS One 2012;7:e38218	1	0	0	0	1	2
Miao et al. Cath Cardiovasc Interv 2012;80:361-67	0	0	1	1	1	3
Zheng et al. J Hypertens 2012;30:901-7	1	1	1	1	1	5
Li et al. Kidney and Blood Press Res 2012;36:98-106	1	1	1	1	1	5
Zhang et al. Lancet 2012;379:815-22	1	1	1	1	1	5
Chen et al. Hong Ling Med J 2013;19:214-21	0	1	0	1	1	3
Xiong et al. J Formos Med Assoc 2014;113:521-6	0	0	1	1	1	3
Bao et al. QJM 2014;107:443-9	0	0	1	1	1	3

Fu et al. Clin Interv Aging 2014;9:301-8	0	0	0	1	1	2
Fu et al. PLoS One 2014;9:e101013	1	0	1	1	1	4
Lin et al. BMC Nephrol 2014;15:36	1	1	1	1	1	5
Luo et al. Stroke 2014;45:2887-93	0	1	1	0	1	3
Liu et al. Renal Failure 2015;37:1323-8	0	0	1	1	1	3
Yang et al. BMC Nephrology 2015;16:16	0	0	1	1	1	3
Luk et al. PLoS One 2015;10:e0134981	0	0	1	1	1	3
Wang et al. Nephrology 2015;20:474-84	1	1	1	1	1	5
Kong et al. Int Urol Nephrol 2015;47:1547-53	1	1	1	1	1	5
Zhao et al. PLoS One 2015;10:e0135462	0	1	0	1	1	3
Peng et al. Eur J Intern Med 2016;29:78-87	0	0	1	1	1	3
Peng et al. Medicine 2016;95:e2740	0	1	0	1	1	3
Guo et al. J Diabetes Complications 2016;30:803-10	0	1	1	1	1	4
He et al. Medicine 2016;95:e3769	1	1	0	1	1	4
Dong et al. Medicine 2017:e5868	0	0	1	1	1	3
Sun et al. Chin Med J 2017;130:57-63	0	0	1	1	1	3
Yeung et al. J Hepatol 2017;S0168-8278	0	0	0	1	1	2
Inoue et al. BMC Nephrol 2017;18:160	1	1	0	1	1	4
Wang et al. BMC Nephrol 2017;18:188	1	1	0	1	1	4
Wang et al. Biomedical Research 2018;29:3062-8	0	0	1	0	1	2
Ma et al. Int Urol Nephrol 2018;50:2239-44	1	1	1	1	1	5
Lin et al. BMJ Open 2018;8:e019097	0	1	1	1	1	4
Wang et al. BMC Nephrology 2018;19:294	1	1	0	1	1	4
Wang et al. PLoS ONE 2018;13:e0193734	1	1	0	1	1	4
Su et al. Eur J Intern Med 2018;57:32-8	1	1	0	1	1	4
Wu et al. Scientific Reports 2018;8:2157	0	1	1	1	1	4
Ye et al. BMC Nephrology 2019;20:457	1	1	1	1	1	5
Ye et al. Medicine 2019;98:e14262	0	0	1	1	1	3
Liu et al. Ann Transl Med 2020;8:2	1	1	0	1	1	4
Agarwal et al. NDT 2005;20:1638-42	1	1	0	0	0	2

Unnikrishann et al. Diabetes Care 2007;30:2019-24	0	0	1	0	1	2
Singh et al. BMC Nephrol 2009;10:4	1	1	1	1	1	5
Varma et al. Nephrol Dial Transpl 2010;25:3011-7	0	1	1	1	1	4
Varma et al. MJAFI 2011;67:9-14	0	0	1	1	1	3
Gallieni et al. Nephrol 2013;18:798-07	1	0	1	1	1	4
Singh et al. BMC Nephrol 2013;14:114	0	1	1	1	1	4
Anupama and Uma. Indian J Nephrol 2014;24:214-21	1	0	1	1	1	4
Anand et al. Kidney Int 2015;88:178-85	1	1	0	1	1	4
Mahapatra et al. Saudi J Kidney Dis Transpl 2016;27:362-70	0	0	0	1	1	2
Trivedi et al. Clin Kidney J 2016;9:438-43	1	0	1	1	1	4
Anupama et al. J Hum Hypertens 2017;31:327-32	1	0	0	1	0	2
Rajput et al. J Diab Metabol	1	1	0	1	1	4
Pradeep et al. Urol Nephrol Open Access J 2018;6:167-71	1	0	0	1	0	2
Tatapudi et al. KI Reports 2019;4:380-9	1	0	1	1	0	3
O'Callaghan-Gordo et al. BMJ Open 2019;9:e023353	1	1	1	1	1	5
Mohanty et al. Int J Environ Res and Public Health	1	0	0	1	1	3
Prodjosudjadi et al. Nephrol 2009;14:669-74	1	1	0	1	0	3
Hosseinpanah et al. BMC Public Health 2009;9:44	1	1	1	1	1	5
Najafi et al. PLoS One 2010;5:e14216	1	1	1	1	1	5
Mahdavi-Mazdeh et al. Renal Failure 2010;32:62-8	1	1	1	1	1	5
Barahimi et al. Iran J Kidney Dis 2011;5:374-9	1	0	0	1	0	2
Najafi et al. Arch Iranian Med 2012;15:70-5	1	0	1	1	1	4
Malekmakan et al. ISRN Nephrol 2013;2013:427230	0	0	1	1	1	3
Khajehdehi et al. Iranian J Kidney Dis 2014;8:109-15	1	1	1	1	1	5
Naghbi et al. Iranian J Kidney Dis 2015;9:449-53	1	0	1	1	1	4
Panahi et al. Iranian J Kidney Dis 2016;10:274-81	1	1	1	1	1	5
Sepanlou et al. PLoS One 2017;12:e0176540	1	1	0	1	0	3
Bakhshayeshkaram et al. Galen Med J 2018;7:e935	1	0	0	1	0	2
Mahmoodpoor et al. J Renal Inj Prev 2018;7:124-8	1	0	0	1	0	2

Piri-Ardakani et al. Ann Med Health Sci Res 2018;8:26670	1	0	1	1	1	4
Nakamura et al. Circ J 2006;70:954-9	1	1	1	1	1	5
Iseki et al. Hypertens Res 2007;30:55-62	1	1	0	1	0	3
Koganei et al. Circ J 2008;72:179-85	0	0	1	1	1	3
Iguchi et al. Am J Cardiol 2008;102:1056-9	1	1	0	0	0	2
Nakamura et al. Hypertens Res 2009;32:920-6	0	0	1	1	1	3
Takamatsu et al. BMC Nephrol 2009;10:34	0	0	1	1	1	3
Hamaguchi et al. Circ J 2009;73:1442-7	0	0	1	1	1	3
Higashiyama et al. Hypertens Res 2009;32:450-4	1	0	1	1	1	4
Kohagura et al. Clin Exp Nephrol 2009;13:614-20	1	1	0	1	0	3
Imai et al. Clin Exp Nephrol 2009;13:621-30	1	1	1	1	1	5
Kiyosue et al. Circ J 2010;74:786-91	0	0	1	1	1	3
Bouchi et al. Hypertens Res 2010;33:1298-304	0	0	1	1	1	3
Nagata et al. Nephrol Dial Transpl 2010;25:2557-64	1	0	0	1	0	2
Yano et al. Atherosclerosis 2011;219:273-9	0	0	1	1	1	3
Takata et al. Aging Clin Exp Res 2011;23:223-30	0	1	1	1	1	4
Konishi et al. Circ J 2011;75:2372-8	0	0	1	1	1	3
Kudo et al. Clin Exp Nephrol 2011;15:235-41	1	1	0	0	0	2
Miyatake et al. Environ Health Prev Med 2011;3:191-5	1	1	1	1	0	4
Shimizu et al. Stroke 2011;42:2531-7	1	1	1	1	1	5
Kudo et al. Clin Exp Nephrol 2012;16:564-9	0	0	1	1	1	3
Hanai et al. Nephrol Dial Transpl 2012;27:1070-5	0	0	0	0	0	0
Kuwashiro et al. Cerebrovasc Dis 2012;33:141-9	0	0	0	1	0	1
Dan et al. Circ J 2012;76:2266-72	0	0	0	1	0	1
Ohno et al. Kidney Blood Press Res 2012;36:139-48	1	1	0	1	0	3
Wakasugi et al. Clin Exp Nephrol 2012;16:259-68	1	1	0	1	0	3
Furukawa et al. Eur J Endocrinol 2013;169:239-46	0	0	0	1	0	1
Yano et al. Am J Nephrol 2013;38:195-203	0	0	1	1	1	3
Konta et al. Clin Exp Nephrol 2013;17:805-10	1	1	1	1	1	5

Noborisaka et al. Environ Health Prev Med 2013;18:466-76	1	1	0	1	0	3
Yamada et al. Arch Gerontol Geriatr 2013;57:328-32	0	1	0	1	0	2
Shimizu et al. Atherosclerosis 2014;2014:233:525-9	0	1	1	1	1	4
Ishida et al. J Hypertension 2014;32:1435-43	1	1	1	1	1	5
Tsuruya et al. Atherosclerosis 2014;233:260-7	1	1	1	1	1	5
Tanaka et al. Nephrology 2015;20:531-8	1	1	0	0	0	2
Nagai et al. PloS One 2019;11:e0156792	1	1	1	1	1	5
Nakahashi et al. Heart Vessels 2017;32:22-9	0	0	1	1	1	3
Hara et al. Clin Exp Nephrol 2017;21:275-82	0	0	0	1	0	1
Tokoroyama et al. Nephrol Dial Transpl 2017;32:2035-42	0	0	1	1	1	3
Esato et al. Chest 2017;152:1266-75	0	0	0	1	0	1
Hirata et al. Eur J Prev Cardiol 2017;24:505-23	0	1	1	1	1	4
Nishikawa et al. Clin Exp Nephrol 2017;21:316-23	1	1	1	1	1	5
Yokomichi et al. J Epidemiol 2017;27:S98-106	0	1	0	1	0	2
Dan et al. Cardiorenal Med 2018;8:151-9	0	0	0	1	0	1
Matsumoto et al. World J Urol 2018;36:	0	0	1	1	1	3
Yanagisawa et al. Heart Rhythm 2018;15:348-54	0	0	1	1	1	3
Kuwabara et al. Nutrients 2018;10:1011	1	1	0	1	0	3
Kichikawa et al. Cardiovasc Intervent Radiol 2019;42:358-64	0	0	0	1	0	1
Fujii et al. Nephrol 2019;24:670-73	1	1	0	1	0	3
Toda et al. Nephron 2019;142:91-7	1	1	0	1	0	3
Kashihara et al. Kidney Int Rep 2019;4:1248-60	0	1	0	1	0	2
Nagai et al. PloS One 2019;14:e0216432	0	1	0	1	0	2
Tsuyuki et al. Thromb Res 2020;187:39-47	0	0	1	1	1	3
Hooi et al. Kidney Int 2013;84:1034-40	1	0	0	1	0	2
Abougambou et al. Diabetes Metab Syndr 2013;7:64-7	0	0	1	1	1	3
Ismail et al. BMC Cardiovasc Discord 2018;18:184	0	1	1	1	1	4
Saminathan et al. BMC Nephrol 2020;21:344	1	0	0	1	0	2
Sharma et al. Am J Kidney Dis 2010;56:915-27	0	0	0	1	1	2

Sharma et al. Am J Kidney Dis 2010;56:915-27	1	1	0	1	1	4
Cravedi et al. BMJ Open 2012;2:e001357	1	1	0	1	1	4
Sharma et al. J Nepal Med Assoc 2013;52:205-12	1	1	0	1	0	3
Jafar et al. Nephrol Dial Transpl 2009;24:2111-6	1	1	0	1	1	4
Ishtiaque et al. PLoS One 2014;9:e85652	1	0	1	1	1	4
Jessani et al. BMC Nephrol 2014;15:90	1	0	1	1	1	4
Feng et al. Nephrol Dial Transplant 2019;34:1723-30	0	0	0	1	1	2
NNHeS renal report http://goo.gl/XKADci	*	*	*	*	*	*
Nang et al. Am J Epidemiol 2009;169:1456-62	1	1	0	1	1	4
Sabanayagam et al. Nephrol Dial Transpl 2010;25:2564-70	1	1	0	1	1	4
Tay et al. Acta Cardiol 2010;65:211-6	0	1	1	1	1	4
Feng et al. J Am Geriatr Soc 2012;60:1208-14	1	0	1	1	1	4
Low et al. Ann Acad Med Singapore 2015;44:164-71	0	0	0	1	1	2
Lew et al. Nephron 2018;138:202-13	1	1	1	1	1	5
Han et al. BMC Nephrol 2009;10:39	0	0	1	1	1	3
Shin et al. BMC Nephrol 2011;12:29	1	0	1	1	1	4
Yang et al. Nephrol Dial Transplant 2011;26:3249-255	0	1	1	1	1	4
KNHANES 2011 α	1	1	1	1	1	5
Park et al. Cardiovasc Therapeutics 2012;30:5-11	0	0	0	1	1	2
Kim et al. BMC Public Health 2012;12:960	1	1	0	1	1	4
Kweon et al. Diabetes Res Clin Pract 2012;3:492-8	1	1	1	1	1	5
Choi et al. Nephrol Dial Transplant 2012;27:3868-74	0	1	1	1	1	4
Oh et al. Nephrol Dial Transpl 2012;27:2284-90	1	1	1	1	1	5
Kim et al. Jap J Clin Oncol 2013;43:1243-48	0	0	1	1	1	3
Hwang et al. Am J Nephrol 2014;40:345-52	0	1	1	1	1	4
Mok et al. PLoS One 2016;11:e0153429	1	1	1	1	1	5
Lee et al. J Clin Sleep Med 2017;13:1145-52	1	0	0	1	1	3
Kim et al. Medicine 2018;97:e13099	1	1	1	1	1	5
Kim et al. Int J Cardiol 2018;262:32-7	0	0	1	1	1	3
Cha et al. Circ J 2018;82:2970-5	0	1	0	1	1	3

Lim et al. J Viral Hepa 2019;27:316-22	1	0	0	1	1	3
Athuraliya et al. Kidney Int 2011;80:1212-21	1	1	0	1	1	4
Jayasekara et al. J Epidemiol 2015;25:275-80	1	1	0	0	0	2
Weerathna et al. BioMed Res Int 2018;8178043	0	0	1	1	1	3
Feng et al. Nephrol Dial Transplant 2019;34:1723-30	0	0	0	1	1	2
Ranasinghe et al. BMC Nephrol 2019;20:338	1	1	0	1	1	4
Hsu et al. Am J Kidney Dis 2006;48:727-38	1	1	0	1	1	4
Chou et al. Int Med J 2008;38:402-6	1	0	1	1	1	4
Kang et al. J Occup Environ Med 2007;49:776-9	1	1	1	1	1	5
Chen et al. Maturitas 2008;59:55-61	1	0	0	1	1	3
Wu et al. Am J Med Sci 2008;336:303-8	0	0	1	1	1	3
Cheng et al. Am J Kidney Dis 2008;52:1051-60	1	1	1	1	1	5
Wen et al. Lancet 2008;371:2173-82	1	1	1	1	1	5
Tseng. Clin Biochem 2009;42:1019-24	0	0	1	1	1	3
Lin et al. Nephrol Dial Transplant 2010;25:3230-235	0	1	1	1	1	4
Hsu et al. Nephrology 2011;16:751-7	1	1	1	1	1	5
Lin et al. PLoS One 2012;7:e47960	1	0	1	1	1	4
Lin et al. Cardiovasc Diabetol 2012;11:131	0	1	1	1	1	4
Hsieh et al. Cerebrovascular Disease 2014;37:51-6	0	0	1	1	1	3
Lin et al. Biomed Res Int 2014;24:841497	1	0	1	0	1	3
Lin et al. BMC Nephrol 2014;15:66	0	0	1	1	1	3
Li et al. Intern Med J 2014;44:645-52	1	1	0	1	1	4
Hsieh et al. J stroke Cerebrovasc Dis 2015;24:673-9	0	1	1	1	1	4
Lin et al. Heart Vess 2015;30:441-50	1	1	0	1	1	4
Tsai et al. Eur J Clin Nutr 2015;69:34-9	1	0	1	0	1	3
Yeh et al. Atherosclerosis 2015;239:328-34	0	0	1	1	1	3
Chang et al. Acta Cardiol Sin 2015;31:106-12	1	1	0	1	1	4
Chua et al. Nephrol 2016;21:583-91	*	*	*	*	*	*
Chu et al. J Am Coll Cardiol 2016;67:S58	0	1	0	0	1	2
Lin et al. BMC Cardiovasc Dis 2017;17:242	0	0	1	1	1	3

Lai et al. <i>Kidney Int</i> 2017;92:703-9	1	1	0	1	1	4
Li et al. <i>BMJ Open</i> 2018;8:e021655	0	0	1	1	1	3
Chen et al. <i>Environ Pollut</i> 2018;234:838-45	0	1	0	1	1	3
Lai et al. <i>Family Pract</i> 2018;35:259-65	1	1	0	1	1	4
Wang et al. <i>Atherosclerosis</i> 2018;269:288-93	0	1	1	1	1	4
Tsai et al. <i>Nephron</i> 2018;140:175-84	1	1	1	1	1	5
Chang et al. <i>BMC Neurol</i> 2019;19:180	0	0	0	1	1	2
Taiwan individual participant data	*	*	*	*	*	*
Domrongkitchaiporn et al. <i>J Am Soc Nephrol</i> 2005;16:791-9	1	1	0	1	1	4
Chittinandana et al <i>J Med Assoc Thai</i> 2006;89:S112-20	1	1	1	1	1	5
Perkovic et al. <i>Kidney Int</i> 2008;73:473-9	1	1	1	1	1	5
Ingsathit et al. <i>Nephrol Dial Transplant</i> 2010;25:1567-75	1	1	1	1	1	5
Zaman et al. <i>Diabetes Res Clin Pract</i> 2018;138:238-45	0	1	0	1	1	3
Jitraknatee et al. <i>Sci Rep</i> 2020;10:6205	0	0	1	1	1	3
Ito et al. <i>Nephron Clin Pract</i> 2008;109:c25-32	*	*	*	*	*	*
Tran et al. <i>BMC Res Notes</i> 2017;10:523	1	0	0	1	1	3

^Low risk was defined as 4-5 points; moderate risk as 3 points and high risk of bias was defined as 0-2 points.; *insufficient information provided
CKD=chronic kidney disease

Supplementary appendix 5: Estimated prevalence and number of people with CKD (overall and stage 4-5) in countries of Asia, by cluster, based on studies published between 2010 and 2020

Cluster	Countries	Number of people aged ≥20 years in 2020 (x million)	Overall CKD [#]				Advanced CKD [*]			
			Population-based studies		All studies		Population-based studies		All studies	
			Number of patients (x million; 95% CI)	Prevalence (%; 95% CI)	Number of patients (x million; 95% CI)	Prevalence (%; 95% CI)	Number of patients (x million; 95% CI)	Prevalence (%; 95% CI)	Number of patients (x million; 95% CI)	Prevalence (%; 95% CI)
1	Afghanistan	18.02	3.06 (2.74 to 3.39)	17.0 (15.2 to 18.8) ^(b)	2.77 (2.16 to 3.39)	15.4 (12.0 to 18.8) ^(b)	3.06 (2.74 to 3.39)	17.0 (15.2 to 18.8) ^(b)	0.16 (0.04 to 0.29)	0.9 (0.2 to 1.6) ^(b)
	Pakistan ^(a)	122.00	8.71 (7.79 to 9.64)	17.0 (15.2 to 18.8)	7.89 (6.15 to 9.64)	15.4 (12.0 to 18.8)	8.71 (7.79 to 9.64)	17.0 (15.2 to 18.8) ^(c)	0.46 (0.1 to 0.82)	0.9 (0.2 to 1.6)
2	Bangladesh	105.04	17.23 (2.1 to 32.35)	16.4 (2.0 to 30.8)	20.8 (10.29 to 31.41)	19.8 (9.8 to 29.9)	6.51 (0 to 16.07)	6.2 (0.0 to 15.3)	4.73 (0 to 12.39)	4.5 (0.0 to 11.8)
	Bhutan	0.51	0.07 (0.05 to 0.1)	14.7 (10.6 to 18.9) ^(b)	0.08 (0.06 to 0.1)	15.4 (11.5 to 19.4) ^(b)	0.01 (0 to 0.04)	2.0 (0.0 to 7.2) ^(b)	0.01 (0 to 0.02)	1.3 (0.0 to 4.9) ^(b)
	Nepal	17.55	2.56 (1.81 to 3.32)	14.6 (10.3 to 18.9)	2.56 (1.81 to 3.32)	14.6 (10.3 to 18.9)	0.05 (0.05 to 0.07)	0.3 (0.3 to 0.4)	0.05 (0.05 to 0.07)	0.3 (0.3 to 0.4)
3	Cambodia	10.09	1.31 (1.17 to 1.44)	13.0 (11.6 to 14.3) ^(b)	1.42 (1.05 to 1.8)	14.1 (10.4 to 17.8) ^(b)	0.11 (0 to 0.34)	1.1 (0.0 to 3.4) ^(b)	0.11 (0 to 0.33)	1.1 (0.0 to 3.3) ^(b)
	Laos	4.24	0.55 (0.49 to 0.61)	13.0 (11.6 to 14.3) ^(b)	0.6 (0.44 to 0.76)	14.1 (10.4 to 17.8) ^(b)	0.05 (0 to 0.14)	1.1 (0.0 to 3.4) ^(b)	0.05 (0 to 0.14)	1.1 (0.0 to 3.3) ^(b)
	Myanmar	35.47	4.61 (4.11 to 5.07)	13.0 (11.6 to 14.3) ^(b)	5 (3.69 to 6.31)	14.1 (10.4 to 17.8) ^(b)	0.39 (0 to 1.21)	1.1 (0.0 to 3.4) ^(b)	0.39 (0 to 1.17)	1.1 (0.0 to 3.3) ^(b)
	India	892.94	125.01 (91.08 to 158.94)	14.0 (10.2 to 17.8)	150.01 (107.15 to 192.88)	16.8 (12.0 to 21.6)	21.43 (8.93 to 33.93)	2.4 (1.0 to 3.8)	20.54 (10.72 to 29.47)	2.3 (1.2 to 3.3)
	Indonesia	179.26	23.3 (20.79 to 25.63)	13.0 (11.6 to 14.3) ^(b)	25.28 (18.64 to 31.91)	14.1 (10.4 to 17.8) ^(b)	1.97 (0 to 6.09)	1.1 (0.0 to 3.4) ^(b)	1.97 (0 to 5.92)	1.1 (0.0 to 3.3) ^(b)
	Philippines	66.20	8.61 (7.68 to 9.47)	13.0 (11.6 to 14.3) ^(b)	9.33 (6.88 to 11.78)	14.1 (10.4 to 17.8) ^(b)	0.73 (0 to 2.25)	1.1 (0.0 to 3.4) ^(b)	0.73 (0 to 2.18)	1.1 (0.0 to 3.3) ^(b)
	Timor-Leste	0.68	0.09 (0.08 to 0.1)	13.0 (11.6 to 14.3) ^(b)	0.1 (0.07 to 0.12)	14.1 (10.4 to 17.8) ^(b)	0.007 (0 to 0.023)	1.1 (0.0 to 3.4) ^(b)	0.007 (0 to 0.022)	1.1 (0.0 to 3.3) ^(b)
	Viet Nam	68.26	8.74 (7.71 to 9.69)	12.8 (11.3 to 14.2)	8.74 (7.71 to 9.69)	12.8 (11.3 to 14.2)	0.07 (0 to 0.14)	0.1 (0.0 to 0.2)	0.07 (0 to 0.14)	0.1 (0.0 to 0.2)
	North Korea	17.88	2.32 (2.07 to 2.56)	13.0 (11.6 to 14.3) ^(b)	2.52 (1.86 to 3.18)	14.1 (10.4 to 17.8) ^(b)	0.2 (0 to 0.61)	1.1 (0.0 to 3.4) ^(b)	0.2 (0 to 0.59)	1.1 (0.0 to 3.3) ^(b)
4	Brunei	0.31	0.04 (0.02 to 0.06)	12.2 (5.8 to 18.6) ^(b)	0.06 (0.03 to 0.08)	18.2 (10.8 to 25.7) ^(b)	0.001 (0 to 0.002)	0.4 (0.1 to 0.7) ^(b)	0.001 (0 to 0.002)	0.4 (0.1 to 0.7) ^(b)
	Malaysia	22.11	2.7 (1.28 to 4.11)	12.2 (5.8 to 18.6)	4.02 (2.39 to 5.68)	18.2 (10.8 to 25.7)	0.09 (0.02 to 0.15)	0.4 (0.1 to 0.7)	0.09 (0.02 to 0.15)	0.4 (0.1 to 0.7)
5	China	1102.05	105.8 (83.76 to 126.74)	9.6 (7.6 to 11.5)	165.31 (150.98 to 179.63)	15.0 (13.7 to 16.3)	2.2 (1.1 to 3.31)	0.2 (0.1 to 0.3)	28.65 (22.04 to 35.27)	2.6 (2.0 to 3.2)
	Thailand	53.87	7.76 (7.11 to 8.4)	14.4 (13.2 to 15.6)	11.42 (7.27 to 15.62)	21.2 (13.5 to 29.0)	0.59 (0.38 to 0.75)	1.1 (0.7 to 1.4)	1.89 (0 to 4.58)	3.5 (0.0 to 8.5)
	Sri Lanka	14.68	1.16 (0 to 2.83)	7.9 (0.0 to 19.3)	2.85 (1.51 to 4.2)	19.4 (10.3 to 28.6)	0 (0 to 0)	0.0 (0.0 to 0.0)	0.35 (0.19 to 0.5)	2.4 (1.3 to 3.4)
	Maldives	0.41	0.04 (0.02 to 0.06)	9.9 (5.7 to 14.2) ^(b)	0.08 (0.06 to 0.1)	19.6 (13.8 to 25.4) ^(b)	0 (0 to 0)	0.6 (0.2 to 0.9) ^(b)	0.01 (0.01 to 0.02)	3.5 (1.9 to 5.1) ^(b)
	Taiwan	19.58	1.1 (0.25 to 1.92)	5.6 (1.3 to 9.8)	4.62 (3.95 to 5.29)	23.6 (20.2 to 27.0)	0.12 (0.11 to 0.13)	0.6 (0.6 to 0.6)	1.15 (0.88 to 1.43)	5.9 (4.5 to 7.3)
6	Japan	105.03	14.39 (10.4 to 18.38)	13.7 (9.9 to 17.5)	27.41 (24.47 to 30.25)	26.1 (23.3 to 28.8)	0.21 (0.11 to 0.32)	0.2 (0.1 to 0.3)	5.46 (3.99 to 6.83)	5.2 (3.8 to 6.5)
	Singapore	4.87	0.76 (0.71 to 0.81)	15.6 (14.5 to 16.7)	1.43 (1.03 to 1.82)	29.3 (21.1 to 37.4)	0.07 (0.05 to 0.09)	1.5 (1.1 to 1.8)	0.22 (0.11 to 0.32)	4.5 (2.3 to 6.6)
	South Korea	42.36	2.97 (2.16 to 3.77)	7.0 (5.1 to 8.9)	6.86 (5.8 to 7.88)	16.2 (13.7 to 18.6)	1.61 (1.4 to 1.82)	3.8 (3.3 to 4.3)	1.61 (0.42 to 2.8)	3.8 (1.0 to 6.6)
7	Iran	57.68	5.88 (3.98 to 7.79)	10.2 (6.9 to 13.5)	7.9 (5.54 to 10.21)	13.7 (9.6 to 17.7)	0.29 (0 to 0.87)	0.5 (0.0 to 1.5)	0.23 (0.12 to 0.35)	0.4 (0.2 to 0.6)
8	Mongolia	2.04	0.16 (0.13 to 0.19)	7.8 (6.2 to 9.5)	0.16 (0.13 to 0.19)	7.8 (6.2 to 9.5)	0.03 (0.02 to 0.05)	1.6 (0.8 to 2.4)	0.03 (0.02 to 0.05)	1.6 (0.8 to 2.4)

	Total	2963.12	348.93 (259.5 to 437.36)	11.8 (8.8 to 14.8)	469.22 (371.14 to 567.23)	15.8 (12.5 to 19.1)	48.52 (22.7 to 81.43)	1.6 (0.8 to 2.7)	69.17 (38.71 to 105.85)	2.3 (1.3 to 3.6)
--	--------------	----------------	---------------------------------	---------------------------	----------------------------------	----------------------------	------------------------------	-------------------------	--------------------------------	-------------------------

#defined as eGFR <60 ml/min/1.73m² or evidence of proteinuria; *defined as eGFR <30 ml/min/1.73m²

(a) Data on people aged 20-39 years were unavailable; CKD prevalence was therefore estimated in people aged 40 years or older;

(b) Prevalence of CKD (overall and advanced) was estimated based on data from others countries included in the same cluster for which CKD prevalence data were available using a random effects meta-analysis

(c) Prevalence for overall CKD were used in place of those for advanced CKD, because of no available data for advanced CKD.

CKD=chronic kidney disease; CI=confidence interval